DBV Technologies S.A. (LON:0QAJ)

Market Cap	617.76M +200.1%
Revenue (ttm)	3.80M +33.1%
Net Income	-132.61M
EPS	-0.45
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	146
Open	2.445
Previous Close	2.298
Day's Range	2.402 - 2.490
52-Week Range	1.440 - 4.460
Beta	-0.24
Analysts	n/a
Price Target	n/a
Earnings Date	Jul 16, 2026

About DBV Technologies

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. The company’s earlier stage research programs include celiac disease. ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2002
• Employees: 170
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0QAJ

Financial Performance

In 2025, DBV Technologies's revenue was $5.64 million, an increase of 35.77% compared to the previous year's $4.15 million. Losses were -$146.95 million, 29.0% more than in 2024.

Financial numbers in USD

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Aug 12, 2026

Data Sources Report a data error